Title	Chemoradiation in Cancer Therapy [electronic resource] / edited by Hak Choy
Imprint	Totowa, NJ : Humana Press : Imprint: Humana Press, 2003
Connect to	http://dx.doi.org/10.1007/978-1-59259-325-5
Descript	XII, 420 p. online resource

The combination of chemotherapeutic drugs and radiation to treat solid tumors has now become a common treatment option in many clinical settings. In Chemoradiation in Cancer Therapy, internationally recognized experts in cancer biology and clinical research review the present status of these multimodality approaches to the management of solid tumors and speculate on possible future strategies for their use. As part of their comprehensive survey, the authors detail applications of combined modality therapy in lung, esophageal, breast, gastric, pancreatic, colon, and rectal cancers. They also show how radiation interacts with such chemotherapeutic agents as the platinum complexes, taxanes, and gemcitabine in the treatment of malignant gliomas, and head and neck cancer. Rounding out the presentation is a review of how to integrate new specific molecular-targeted agents into future multimodality therapy. Here the discussion centers on the antibody for the epidermal growth factor receptor (EGFR), antiangiogenesis agents, farnesyltransferase inhibitors (FTIs), gene therapies, and signaling pathway inhibitors in combination with radiotherapy, and with or without classical chemotherapeutic agents. State-of-the-art and forward-looking, Chemoradiation in Cancer Therapy offers oncologists a thorough understanding of today's best current and future strategies available for the treatment of solid tumors by chemoradiation therapy

I. General/Background -- 1 Chemoradiation: Biological Principles and Perspectives -- 2 Fluoropyrimidines as Radiation Sensitizers -- II. Mechanisms of Interaction of Specific Chemotherapeutic Agents with Radiation -- 3 The Role of Platinum Complexes in Combined Modality Therapy -- 4 Taxanes in Combined Modality Therapy -- 5 Camptothecin Radiation Sensitization -- 6 The Role of Gemcitabine in Combined Modality Therapy -- III. Clinical Applications -- 7 Chemoradiation Strategies for Patients with Malignant Gliomas -- 8 Combined Modality Strategies in the Treatment of Head and Neck Cancer -- 9 The Role of Combined Modality Therapy for Stage III Nonsmall-Cell Lung Cancer -- 10 Combined Modality Treatment of Small-Cell Lung Cancer -- 11 The Role of Chemoradiation in the Management of Esophageal Cancer -- 12 Combined Modality Therapy in Locally Advanced Breast Cancer -- 13 Combined Modality Therapy for Gastric, Pancreatic, and Biliary Tract Carcinomas -- 14 Chemoradiation in Therapy for Colon and Rectum Carcinoma -- 15 Chemoradiotherapy in Muscle-Invasive Bladder Cancer -- 16 The Role of Combined Chemotherapy and Radiation Therapy in the Treatment of Gynecologic Malignancies -- IV. Specific Molecular Targeted Agents -- 17 Overview of Specific Molecular Targeted Agents for Combined Modality Therapy -- 18 Receptor Tyrosine Kinases as Therapeutic Targets in Solid Tumors -- 19 Adenoviral p53 Gene Therapy Strategies in Nonsmall-Cell Lung Cancer -- 20 Tumor Microvasculature as a Therapeutic Target During Radiotherapy -- 21 Cancer Drug Discovery and Development: Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancer -- 22 The Role of Cyclooxygenase-2 Inhibitors in Combined Modality Therapy